Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group
- PMID: 8353925
- DOI: 10.1161/01.cir.88.3.975
Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group
Abstract
Background: The renarrowing process after successful percutaneous transluminal coronary angioplasty (PTCA) is now believed to be caused by a response-to-injury vessel wall reaction. The magnitude of this process can be assessed by the change in minimal lumen diameter (MLD) at follow-up angiography. The aim of the present study was to find independent patient-related, lesion-related, and procedure-related risk factors for this luminal narrowing process. A model that accurately predicts the amount of luminal narrowing could be an aid in patient or lesion selection for the procedure, and it could improve assessment of medium-term (6 months) prognosis. Modification or control of the identified risk factors could reduce overall restenosis rates, and it could assist in the selection of patients at risk for a large loss in lumen diameter. This population could then constitute the _target population for pharmacological intervention studies.
Methods and results: Quantitative angiography was performed on 666 successfully dilated lesions at angioplasty and at 6-month follow-up. Multivariate linear regression analysis was performed to obtain variables with an independent contribution to the prediction of the absolute change in minimal lumen diameter. Diabetes mellitus, duration of angina < 2.3 months, gain in MLD at angioplasty, pre-PTCA MLD, lesion length > or = 6.8 mm, and thrombus after PTCA were independently predictive of change in MLD. Overall prediction of the model was poor, however, percentage-correct classification for a predicted change between -0.1 to -0.4 mm was approximately 10%. Lesions showing no change or regression (change > -0.1 mm) and lesions showing large progression (< or = -0.4 mm) were more predictable (correct classification, 59.5% and 49.7%, respectively).
Conclusions: Renarrowing after successful PTCA as determined with contrast angiography is a process that cannot be accurately predicted by simple clinical, morphological, and lesion characteristics.
Similar articles
-
Luminal narrowing after percutaneous transluminal coronary angioplasty. A multivariate analysis of clinical, procedural and lesion related factors affecting long-term angiographic outcome in the PARK study. Post-Angioplasty Restenosis Ketanserin.J Invasive Cardiol. 1994 Jun;6(5):160-71. J Invasive Cardiol. 1994. PMID: 10155065 Clinical Trial.
-
Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.Eur Heart J. 1995 Oct;16(10):1331-46. doi: 10.1093/oxfordjournals.eurheartj.a060740. Eur Heart J. 1995. PMID: 8746901
-
Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.J Cardiovasc Pharmacol. 1993;22 Suppl 4:S45-57. J Cardiovasc Pharmacol. 1993. PMID: 7523772 Clinical Trial.
-
Coronary restenosis after optimal (stent-like) initial angiographic results obtained by traditional balloon angioplasty.G Ital Cardiol. 1997 Jul;27(7):645-53. G Ital Cardiol. 1997. PMID: 9282284 Review.
-
Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials.Am Heart J. 1993 May;125(5 Pt 1):1394-408. doi: 10.1016/0002-8703(93)91013-5. Am Heart J. 1993. PMID: 8480594 Review.
Cited by
-
Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis.BMC Cardiovasc Disord. 2016 Sep 8;16(1):177. doi: 10.1186/s12872-016-0355-7. BMC Cardiovasc Disord. 2016. PMID: 27608682 Free PMC article. Review.
-
The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty.Clin Cardiol. 2004 Mar;27(3):163-8. doi: 10.1002/clc.4960270314. Clin Cardiol. 2004. PMID: 15049386 Free PMC article.
-
The St Vincent Task Force for diabetes: report of the cardiovascular disease subgroup.Heart. 1996 Aug;76(2):107-8. doi: 10.1136/hrt.76.2.107. Heart. 1996. PMID: 8795470 Free PMC article. No abstract available.
-
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.Am J Pathol. 1999 Feb;154(2):355-63. doi: 10.1016/S0002-9440(10)65282-0. Am J Pathol. 1999. PMID: 10027394 Free PMC article.
-
Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients.Cardiovasc Diabetol. 2013 Jan 10;12:12. doi: 10.1186/1475-2840-12-12. Cardiovasc Diabetol. 2013. PMID: 23305356 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources